There are many expensive and innovative drugs in the pipeline and there is pressure from payers, legislators, and the Trump administration to lower drug prices. Biosimilars are one option to contain increasing pharmacy costs. Biosimilars have been in the global market since 2006, but they have been slow to enter the U.S. market. As of July 2018, the United States has seen only four biosimilars launched under the regulatory approval pathway for biosimilars.
In this article, Milliman’s Jennifer Carioto and Harsha Mirchandani list several barriers hindering the entry of biosimilars in the U.S. marketplace. They also provide perspective on potential paths that may remove or reduce some of the barriers.